Skip to content
MedsAcross

Medicine

Naropin 200 mg/100 mL injection

Ropivacaine · Epidural, infiltration · Fresenius Kabi
Available on requestPrescription onlyUS FDA

Naropin 200 mg/100 mL injection is a prescription medicine containing Ropivacaine for epidural, infiltration use, marketed by Fresenius Kabi, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Solutions should be stored at 20ºC to 25°C (68ºF to 77°F), excursions…

Key facts

Active ingredient (INN)
Ropivacaine
Brand
Naropin
Strength
200 mg/100 mL
Dosage form
Injection
Route
Epidural, infiltration
Packs
24 bags of 100 mL, 12 bottles of 100 mL and 1 more
Marketing authorisation holder
Fresenius Kabi
Manufacturer
Fresenius Kabi
Origin register
US FDA, United States
Storage
Solutions should be stored at 20ºC to 25°C (68ºF to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
24 September 1996
Identifiers
RxCUI 1734084, 1734086, 1734090 +7DailyMed set ID c6613708-c1f7-4f5c-91a3-ebbc1d7905c6, dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89NDC 63323-285Application NDA020533

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
24 bag in 1 case / 100 mL in 1 bag63323-285-61Fresenius Kabi31 May 2011
12 bottle in 1 case / 100 mL in 1 bottle63323-285-65Fresenius Kabi31 May 2011
12 bottle in 1 case / 100 mL in 1 bottle63323-285-67Fresenius Kabi4 August 2009
12 bottle in 1 case / 100 mL in 1 bottle63323-285-68Fresenius Kabi4 August 2009

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 24 September 1996Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Ropivacaine 200 mg/100 mL injection.

Compare all 2

Other strengths and forms of Ropivacaine

Clinical summary

Ropivacaine is an amide local anesthetic indicated for the production of local or regional anesthesia for surgery and for acute pain management. It is available as injection for epidural, infiltration and perineural use. MedsAcross supplies Ropivacaine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Ropivacaine

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Naropin 200 mg/100 mL injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.